LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | NVP-AEW541 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3906 | 3772 | 1.0356 | 1.0517 |
| SK-BR-3 | NVP-AEW541 | 10 | uM | LJP5 | 72 | hr | 1476 | 1451 | 3772 | 0.3850 | -0.0127 |
| SK-BR-3 | PHA-665752 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 4062 | 3772 | 1.0769 | 1.1124 |
| SK-BR-3 | PHA-665752 | 0.12 | uM | LJP5 | 72 | hr | 1476 | 4086 | 3772 | 1.0832 | 1.1209 |
| SK-BR-3 | PHA-665752 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 4197 | 3772 | 1.1125 | 1.1634 |
| SK-BR-3 | PHA-665752 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 4205 | 3772 | 1.1148 | 1.1667 |
| SK-BR-3 | PHA-665752 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 3662 | 3772 | 0.9713 | 0.9574 |
| SK-BR-3 | PHA-665752 | 10 | uM | LJP5 | 72 | hr | 1476 | 928 | 3772 | 0.2461 | -0.2911 |
| SK-BR-3 | PI103 | 0.04 | uM | LJP6 | 72 | hr | 1476 | 3483 | 3643 | 0.9580 | 0.9379 |
| SK-BR-3 | PI103 | 0.12 | uM | LJP6 | 72 | hr | 1476 | 2683 | 3643 | 0.7365 | 0.5804 |
| SK-BR-3 | PI103 | 0.37 | uM | LJP6 | 72 | hr | 1476 | 1954 | 3643 | 0.5373 | 0.2404 |
| SK-BR-3 | PI103 | 1.11 | uM | LJP6 | 72 | hr | 1476 | 1687 | 3643 | 0.4637 | 0.1073 |
| SK-BR-3 | PI103 | 3.33 | uM | LJP6 | 72 | hr | 1476 | 1542 | 3643 | 0.4241 | 0.0336 |
| SK-BR-3 | PI103 | 10 | uM | LJP6 | 72 | hr | 1476 | 1389 | 3643 | 0.3816 | -0.0470 |
| SK-BR-3 | Dovitinib | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2818 | 3772 | 0.7472 | 0.6112 |
| SK-BR-3 | Dovitinib | 0.12 | uM | LJP5 | 72 | hr | 1476 | 2818 | 3772 | 0.7472 | 0.6116 |
| SK-BR-3 | Dovitinib | 0.37 | uM | LJP5 | 72 | hr | 1476 | 2511 | 3772 | 0.6656 | 0.4796 |
| SK-BR-3 | Dovitinib | 1.11 | uM | LJP5 | 72 | hr | 1476 | 2571 | 3772 | 0.6816 | 0.5065 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 1476 | 1954 | 3772 | 0.5181 | 0.2299 |
| SK-BR-3 | Dovitinib | 10 | uM | LJP5 | 72 | hr | 1476 | 1715 | 3772 | 0.4546 | 0.1163 |
| SK-BR-3 | GSK 690693 | 0.04 | uM | LJP5 | 72 | hr | 1476 | 2607 | 3772 | 0.6916 | 0.5222 |
| SK-BR-3 | GSK 690693 | 0.12 | uM | LJP5 | 72 | hr | 1476 | 2592 | 3772 | 0.6875 | 0.5160 |
| SK-BR-3 | GSK 690693 | 0.37 | uM | LJP5 | 72 | hr | 1476 | 2605 | 3772 | 0.6905 | 0.5205 |
| SK-BR-3 | GSK 690693 | 1.11 | uM | LJP5 | 72 | hr | 1476 | 2793 | 3772 | 0.7404 | 0.6014 |
| SK-BR-3 | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 1476 | 2884 | 3772 | 0.7646 | 0.6400 |